ArticleNature medicine2024
Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Open access · hybridAbstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.9field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
Corrections and comments
- Erratum for
Authors and funding
40 authors at 9 institutions in 1 country.
Matthew D GalskyDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.ORCID http://orcid.org/0000-0001-7655-9378
Siamak DaneshmandDepartment of Urology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Sudeh IzadmehrDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-8948-5689
Edgar Gonzalez-KozlovaDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6948-0626
Kevin G ChanDepartment of Urology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0001-6041-1344
Sara LewisDepartment of Radiology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Bassam El AchkarDepartment of Radiology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Tanya B DorffDepartment of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Jeremy Paul CetnarDivision of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA.
Brock O NeilDepartment of Urology, University of Utah, Salt Lake City, UT, USA.
Anishka D'SouzaDivision of Hematology and Medical Oncology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Ronac MamtaniDivision of Hematology and Medical Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
Christos KyriakopoulosDivision of Hematology and Medical Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.ORCID http://orcid.org/0000-0002-6452-7405
Tomi JunGenentech, South San Francisco, CA, USA.
Mahalya Gogerly-MoragodaDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-6982-2078
Rachel BrodyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hui XieHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kai NieHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Geoffrey KellyHuman Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Amir HorowitzTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yayoi KinoshitaDepartment of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ethan EllisDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yohei NosePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Giorgio IoannouPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rafael CabalPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Diane M Del VallePrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
G Kenneth HainesDepartment of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Li WangDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kent W MouwDepartment of Radiation Oncology, Dana-Farber Cancer Institute/Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
Robert M SamsteinDepartment of Radiation Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-6860-2401
Reza MehrazinDepartment of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nina BhardwajTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-1865-4187
Menggang YuDepartment of Biostatistics and Medical Informatics, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Qianqian ZhaoDepartment of Biostatistics and Medical Informatics, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Seunghee Kim-SchulzeTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert SebraTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-9267-2426
Jun ZhuDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0834-8178
Sacha Gnjatic *Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5643-9520
John Sfakianos *Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sumanta K Pal *Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-1712-0848
Icahn School of Medicine at Mount Sinai · USCity of Hope · USUniversity of Wisconsin Carbone Cancer Center · USUSC Norris Comprehensive Cancer Center · USBrigham and Women's Hospital · USOregon Health & Science University · USTisch Hospital · USUniversity of Pennsylvania · USUniversity of Utah · US
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MNCI NIH HHS P30 CA196521NCI NIH HHS U24 CA224319
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.